Double maintains 2 strategies that include SRRK - Scholar Rock Holding Corp.
Current Value
$33.421 Year Return
Current Value
$33.421 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
UVE | -51.36% | $655.76M | +15.53% | 2.76% |
HCI | -43.41% | $1.62B | +29.63% | 1.07% |
RNR | -34.33% | $11.88B | +3.13% | 0.65% |
EG | -33.81% | $15.54B | -8.93% | 2.22% |
ACIC | -31.05% | $556.31M | +12.02% | 0.00% |
HRTG | -30.15% | $451.47M | +38.50% | 0.00% |
ACGL | -26.23% | $35.72B | +8.14% | 0.00% |
CB | -24.54% | $118.70B | +14.40% | 1.22% |
AIZ | -24.46% | $10.48B | +9.60% | 1.47% |
RLI | -23.66% | $7.34B | +10.18% | 1.28% |
ALL | -21.57% | $54.71B | +19.33% | 1.82% |
HALO | -20.75% | $7.89B | +56.93% | 0.00% |
IMRN | -20.11% | $10.80M | -29.66% | 0.00% |
DUK | -19.47% | $92.78B | +23.47% | 3.46% |
BRO | -19.22% | $35.24B | +40.43% | 0.45% |
PGR | -18.90% | $163.47B | +34.83% | 1.75% |
PLMR | -18.42% | $3.65B | +63.15% | 0.00% |
CNA | -18.17% | $13.57B | +15.30% | 3.53% |
HLN | -18.08% | $46.26B | +20.61% | 0.51% |
L | -17.82% | $19.29B | +15.77% | 0.28% |
SeekingAlpha
The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.
SeekingAlpha
The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.
Yahoo
CAMBRIDGE, Mass., March 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for p
Finnhub
By Denny Jacob Scholar Rock's biologics license application for apitegromab was accepted by the Food and Drug Administration. The late-stage biopharmaceutical company said the regulator will...
Yahoo
Scholar Rock’s stock is due to drop by 7.49% following the news, according to pre-market estimates.
Yahoo
CAMBRIDGE, Mass., March 16, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Sc
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ZS | <0.01% | $32.05B | +7.53% | 0.00% |
URGN | <0.01% | $516.26M | -25.33% | 0.00% |
CRESY | <0.01% | $691.57M | +28.00% | 8.96% |
BVN | -<0.01% | $3.93B | -2.46% | 0.00% |
DYN | -0.01% | $1.30B | -59.67% | 0.00% |
NWL | 0.01% | $2.66B | -20.42% | 4.47% |
LAKE | 0.01% | $192.44M | +10.71% | 0.60% |
WABC | 0.01% | $1.35B | +3.01% | 3.50% |
GPOR | -0.01% | $3.27B | +14.37% | 0.00% |
LSPD | 0.01% | $1.39B | -35.35% | 0.00% |
OSW | -0.01% | $1.72B | +24.49% | 0.74% |
ICLR | 0.01% | $14.46B | -46.70% | 0.00% |
HTHT | -0.01% | $11.52B | -4.99% | 0.00% |
IOVA | 0.01% | $1.17B | -75.98% | 0.00% |
DT | -0.02% | $14.49B | +4.26% | 0.00% |
DUOL | -0.02% | $14.25B | +42.81% | 0.00% |
NWSA | -0.02% | $15.09B | +1.57% | 0.75% |
PRDO | 0.02% | $1.68B | +44.82% | 1.99% |
THRY | -0.02% | $583.34M | -39.50% | 0.00% |
AES | -0.02% | $8.83B | -30.79% | 5.65% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 39.32% | $48.81M | 0.69% |
CNYA | 28.92% | $221.36M | 0.6% |
ASHR | 26.41% | $2.66B | 0.65% |
LIT | 23.53% | $950.86M | 0.75% |
REMX | 22.15% | $268.01M | 0.56% |
GXC | 19.72% | $478.20M | 0.59% |
CQQQ | 18.20% | $1.12B | 0.65% |
KBA | 18.01% | $208.91M | 0.56% |
FLCH | 17.05% | $177.61M | 0.19% |
USL | 16.63% | $47.09M | 0.85% |
MCHI | 16.37% | $6.46B | 0.59% |
CXSE | 16.31% | $433.82M | 0.32% |
EWX | 15.73% | $660.02M | 0.65% |
DBO | 15.32% | $199.76M | 0.77% |
BNO | 15.04% | $96.15M | 1% |
OILK | 14.69% | $67.10M | 0.69% |
BATT | 14.64% | $58.83M | 0.59% |
DBE | 14.53% | $54.74M | 0.77% |
CHIQ | 14.23% | $260.60M | 0.65% |
USO | 13.86% | $947.20M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IAK | -20.56% | $788.23M | 0.39% |
KIE | -18.64% | $973.25M | 0.35% |
LDSF | -17.66% | $114.89M | 0.75% |
TPMN | -17.12% | $33.38M | 0.65% |
LMBS | -16.72% | $4.88B | 0.64% |
FPEI | -16.26% | $1.61B | 0.85% |
TJUL | -13.97% | $169.26M | 0.79% |
BTAL | -13.23% | $393.05M | 1.43% |
RSPA | -13.09% | $293.87M | 0% |
FSIG | -12.89% | $1.31B | 0.55% |
SMIN | -12.51% | $787.59M | 0.75% |
CPSJ | -12.44% | $33.06M | 0.69% |
XLU | -12.36% | $17.43B | 0.09% |
EPI | -12.33% | $3.07B | 0.85% |
VPU | -12.01% | $6.66B | 0.09% |
IDU | -11.76% | $1.38B | 0.39% |
KMLM | -11.36% | $222.39M | 0.9% |
FUTY | -11.35% | $1.66B | 0.084% |
FLIN | -10.77% | $1.78B | 0.19% |
CGSD | -10.59% | $1.10B | 0.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MDIV | <0.01% | $450.86M | 0.68% |
ECH | -<0.01% | $590.86M | 0.6% |
CMF | 0.01% | $3.75B | 0.08% |
MBB | 0.01% | $36.55B | 0.04% |
DIV | 0.02% | $650.17M | 0.45% |
SCHF | -0.02% | $43.93B | 0.06% |
GSEW | 0.02% | $1.19B | 0.09% |
ILCG | -0.03% | $2.25B | 0.04% |
VSS | -0.04% | $8.49B | 0.07% |
ICF | 0.04% | $1.97B | 0.33% |
EUFN | 0.04% | $3.06B | 0.48% |
TAXF | 0.05% | $513.85M | 0.29% |
XCEM | -0.05% | $1.08B | 0.16% |
AOM | -0.05% | $1.45B | 0.15% |
SOYB | 0.06% | $25.67M | 0.22% |
IAI | -0.06% | $1.39B | 0.4% |
SPMO | -0.07% | $5.50B | 0.13% |
EWZ | -0.08% | $3.35B | 0.59% |
JIRE | 0.08% | $6.67B | 0.24% |
SPMB | -0.08% | $5.90B | 0.04% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OCFT | 44.43% | $250.20M | +206.31% | 0.00% |
APD | 39.80% | $65.02B | +20.64% | 2.44% |
SUNS | 37.09% | $150.46M | -0.80% | 5.73% |
EH | 30.70% | $913.88M | +0.88% | 0.00% |
AVNW | 30.51% | $239.47M | -50.76% | 0.00% |
GNRC | 26.90% | $7.58B | +0.75% | 0.00% |
BECN | 25.56% | $7.65B | +26.32% | 0.00% |
NIU | 25.39% | $313.36M | +169.05% | 0.00% |
LQDA | 23.24% | $1.29B | +2.31% | 0.00% |
OC | 22.72% | $12.20B | -14.49% | 1.84% |
BHVN | 22.22% | $2.82B | -49.44% | 0.00% |
CPSH | 21.82% | $23.24M | -13.51% | 0.00% |
STG | 21.82% | $28.35M | -43.93% | 0.00% |
PLL | 21.35% | $145.92M | -50.08% | 0.00% |
CRNC | 21.27% | $341.06M | -49.87% | 0.00% |
AIFU | 20.40% | $12.64M | -95.31% | 0.00% |
NECB | 19.08% | $328.15M | +49.68% | 2.19% |
LSTR | 18.33% | $5.20B | -22.64% | 0.95% |
SMCI | 18.13% | $20.33B | -66.08% | 0.00% |
CSIQ | 17.60% | $610.79M | -53.29% | 0.00% |